CT of an actively-hemorrhaging liver laceration in a 9-year-old child

1990 ◽  
Vol 20 (7) ◽  
pp. 558-559
Author(s):  
C. Whitten ◽  
C. Grimes ◽  
R. Isler ◽  
M. Curci ◽  
A. Dibbins
Keyword(s):  
Liver Laceration

scholarly journals Uncontrolled Hemorrhagic Shock Modeled via Liver Laceration in Mice with Real Time Hemodynamic Monitoring

10.3791/55554 ◽  
2017 ◽  
Author(s):  
Mitchell Dyer ◽  
Shannon Haldeman ◽  
Andres Gutierrez ◽  
Lauryn Kohut ◽  
Anirban Sen Gupta ◽  
...  
Keyword(s):  
Hemorrhagic Shock ◽  
Real Time ◽  
Hemodynamic Monitoring ◽  
Liver Laceration

scholarly journals Unexplained liver laceration after metastasis radiofrequency ablation

2009 ◽  
Vol 15 (40) ◽  
pp. 5103
Author(s):  
Esther Uña ◽  
Javier Trueba ◽  
Jose Manuel Montes
Keyword(s):  
Radiofrequency Ablation ◽  
Liver Laceration

Traumatic Intrahepatic Portosystemic Venous Shunt: A Rare Complication of Grade V Liver Laceration

2007 ◽  
Vol 63 (6) ◽  
pp. 1230-1233 ◽  
Author(s):  
Timothy E. Oppermann ◽  
Alain C. Corcos ◽  
Larry M. Jones ◽  
Roger R. Barrette ◽  
Jorge R. Varcelotti
Keyword(s):  
Rare Complication ◽  
Liver Laceration ◽  
Venous Shunt

An unusual presentation of liver laceration in a 13-yr-old football player

1993 ◽  
Vol 25 (6) ◽  
pp. 667???672 ◽  
Author(s):  
PAUL R. STRICKER ◽  
BRIAN H. HARDIN ◽  
JAMES C. PUFFER
Keyword(s):  
Football Player ◽  
Unusual Presentation ◽  
Liver Laceration

PRT064445 but Not Recombinant Fviia Reverses Rivaroxaban Induced Anticoagulation As Measured by Reduction in Blood Loss in a Rabbit Liver Laceration Model

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 3414-3414 ◽  
Author(s):  
Stanley J Hollenbach ◽  
Genmin Lu ◽  
Siusze Tan ◽  
Gail Lee ◽  
Hutchaleelaha Athiwat ◽  
...  
Keyword(s):  
Blood Loss ◽  
Bolus Injection ◽  
Equilibrium Dialysis ◽  
Free Fraction ◽  
Rabbit Liver ◽  
Bolus Administration ◽  
Total Blood ◽  
Unbound Fraction ◽  
Liver Laceration ◽  
Pharmacodynamic Markers

Abstract Abstract 3414 We used a modified rabbit liver laceration model to demonstrate the effects of PRT064445, a recombinant fXa derivative, to reverse rivaroxaban induced anticoagulation as measured by reduction of blood loss, decrease of unbound fraction of rivaroxaban in plasma and relevant pharmacodynamic markers: anti-fXa activity, prothrombin (PT) and activated thromboplastin (aPTT) times. Recombinant fVIIa (rfVIIa) was tested in the same model for comparison. Anesthetized rabbits were administered vehicle or 1 mg/kg rivaroxaban via IV bolus injection. After 30 minutes to allow the rivaroxaban to biodistribute, vehicle, PRT064445 or rfVIIa was administered as a bolus injection followed by laceration of two liver lobes (5× each lobe: 1-cm long and 3-mm deep incisions with scalpel blade) and blood loss collected on pre-weighed gauze over 15 minutes. Blood loss due to rivaroxaban anticoagulation represented approximately 10% of the animal's total blood volume. Total rivaroxaban concentration in plasma was measured by LC-MS/MS. Free fraction of rivaroxaban (non-protein, non-PRT064445 bound) was assessed using equilibrium dialysis method followed by LC-MS/MS quantitation. Anti-fXa activity was measured using a modified chromogenic LMW heparin kit. PT and aPTT was measured using commercial reagents (HemosIL). Anticoagulation by rivaroxaban (1.65 μM average plasma concentration at 30 min time point) resulted in 2.3-fold and 1.9-fold prolongation of PT and aPTT, respectively, and increased blood loss by 3.2-fold over vehicle. PRT064445 (75 mg/rabbit) administration reduced blood loss due to rivaroxaban anticoagulation by >85% and decreased peak anti-fXa activity by 98%, PT by 74%, aPTT by 66% and the free fraction of rivaroxaban in plasma from 26% to <0.5%. In contrast, rfVIIa (150 μg/kg) had no effect on blood loss but reversed PT by 85% and aPTT by 54%. PRT064445 and rfVIIa alone had no effect on blood loss, but rfVIIa decreased PT by 35%. These data demonstrate that PRT064445 can reduce blood loss due to rivaroxaban induced anticoagulation using a single bolus administration. Reduction of blood loss with PRT06445 correlated to the decrease in the free fraction of rivaroxaban in plasma as well as PD markers anti-fXa activity and PT, while rfVIIa decreased PT but had no effect on blood loss. These and our previous data with reversal of enoxaparin-induced anticoagulation in a rat tail transection model indicate that PRT064445 can be used as a universal antidote for both direct and indirect fXa inhibitors. Disclosures: Hollenbach: Portola Pharmaceuticals: Employment. Lu:Portola Pharmaceuticals: Employment. Tan:Portola Pharmaceuticals: Employment. Lee:Portola Pharmaceuticals: Employment. Athiwat:Portola Pharmaceuticals: Employment. Inagaki:Portola Pharmaceuticals: Employment. Sinha:Portola Pharmaceuticals Inc.: Employment.

Sign in / Sign up

Export Citation Format

Share Document